Literature DB >> 11260802

From genetics to pathology: tau and alpha-synuclein assemblies in neurodegenerative diseases.

M Goedert1, M G Spillantini, L C Serpell, J Berriman, M J Smith, R Jakes, R A Crowther.   

Abstract

The most common degenerative diseases of the human brain are characterized by the presence of abnormal filamentous inclusions in affected nerve cells and glial cells. These diseases can be grouped into two classes, based on the identity of the major proteinaceous components of the filamentous assemblies. The filaments are made of either the microtubule-associated protein tau or the protein alpha-synuclein. Importantly, the discovery of mutations in the tau gene in familial forms of frontotemporal dementia and of mutations in the alpha-synuclein gene in familial forms of Parkinson's disease has established that dysfunction of tau protein and alpha-synuclein can cause neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11260802      PMCID: PMC1088427          DOI: 10.1098/rstb.2000.0767

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN: 0962-8436            Impact factor:   6.237


  21 in total

1.  alpha-Internexin aggregates are abundant in neuronal intermediate filament inclusion disease (NIFID) but rare in other neurodegenerative diseases.

Authors:  Nigel J Cairns; Kunihiro Uryu; Eileen H Bigio; Ian R A Mackenzie; Marla Gearing; Charles Duyckaerts; Hideaki Yokoo; Yoichi Nakazato; Evelyn Jaros; Robert H Perry; Steven E Arnold; Virginia M-Y Lee; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2004-05-28       Impact factor: 17.088

Review 2.  Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology.

Authors:  Trevor Tyson; Jennifer A Steiner; Patrik Brundin
Journal:  J Neurochem       Date:  2016-02-10       Impact factor: 5.372

3.  Conserved core of amyloid fibrils of wild type and A30P mutant α-synuclein.

Authors:  Min-Kyu Cho; Hai-Young Kim; Claudio O Fernandez; Stefan Becker; Markus Zweckstetter
Journal:  Protein Sci       Date:  2011-02       Impact factor: 6.725

Review 4.  Prion-like mechanisms in neurodegenerative diseases.

Authors:  Bess Frost; Marc I Diamond
Journal:  Nat Rev Neurosci       Date:  2009-12-23       Impact factor: 34.870

5.  Fragmentation of the Golgi complex of dopaminergic neurons in human substantia nigra: New cytopathological findings in Parkinson's disease.

Authors:  Mónica Tomás; Emma Martínez-Alonso; Narcisa Martínez-Martínez; Mireia Cara-Esteban; José A Martínez-Menárguez
Journal:  Histol Histopathol       Date:  2020-10-20       Impact factor: 2.303

6.  Neuromelanin enhances the toxicity of α-synuclein in SK-N-SH cells.

Authors:  Jie Li; Junfeng Yang; Peng Zhao; Shen Li; Renyun Zhang; Xiaobin Zhang; Dan Liu; Benshu Zhang
Journal:  J Neural Transm (Vienna)       Date:  2011-12-27       Impact factor: 3.575

7.  Spatial patterns of TDP-43 neuronal cytoplasmic inclusions (NCI) in fifteen cases of frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP).

Authors:  Richard A Armstrong; Nigel J Cairns
Journal:  Neurol Sci       Date:  2011-06-07       Impact factor: 3.307

8.  Convergence of heat shock protein 90 with ubiquitin in filamentous alpha-synuclein inclusions of alpha-synucleinopathies.

Authors:  Kunihiro Uryu; Christiane Richter-Landsberg; William Welch; Eveline Sun; Olaf Goldbaum; Erin H Norris; Chi-Tuan Pham; Ikuru Yazawa; Kristen Hilburger; Matthew Micsenyi; Benoit I Giasson; Nancy M Bonini; Virginia M-Y Lee; John Q Trojanowski
Journal:  Am J Pathol       Date:  2006-03       Impact factor: 4.307

9.  A morphometric study of the spatial patterns of TDP-43 immunoreactive neuronal inclusions in frontotemporal lobar degeneration (FTLD) with progranulin (GRN) mutation.

Authors:  Richard A Armstrong; Nigel J Cairns
Journal:  Histol Histopathol       Date:  2011-02       Impact factor: 2.303

Review 10.  The expanding realm of prion phenomena in neurodegenerative disease.

Authors:  Bess Frost; Marc I Diamond
Journal:  Prion       Date:  2009-04-16       Impact factor: 3.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.